Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival-Reference-Cited by-同舟云学术

Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival

Published:2014-10 Issue:10 Volume:38 Page:1173-1176
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Breccia Massimo,Luciano Luigiana,Latagliata Roberto,Castagnetti Fausto,Ferrero Dario,Cavazzini Francesco,Trawinska Malgorzata Monica,Annunziata Mario,Stagno Fabio,Tiribelli Mario,Binotto Gianni,Crisà Elena,Musto Pellegrino,Gozzini Antonella,Cavalli Laura,Montefusco Enrico,Iurlo Alessandra,Russo Sabina,Cedrone Michele,Rossi Antonella Russo,Pregno Patrizia,Endri Mauro,Spadea Antonio,Molica Matteo,Giglio Gianfranco,Celesti Francesca,Sorà Federica,Storti Sergio,D’Addosio Ada,Cambrin Giovanna Rege,Isidori Alessandro,Sica Simona,Abruzzese Elisabetta,Speccha Giorgina,Rosti Gianantonio,Alimena Giuliana

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference16 articles.

1. The pre-therapeutic classification of co-morbidity in chronic disease;Feinstein;J Cron Dis,1970

2. Charlson comorbidity index as a predictor of long-term outcome after surgery for non-small cell lung cancer;Birim;Eur J Cardiothorac Surg,2005

3. Charlson comorbidity index and adult comorbidity evaluation-27 scores might predict treatment compliance and development of pleural effusions in elderly patients with chronic myeloid leukemia treated with second-line dasatinib;Breccia;Haematologica,2011

4. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet;Baccarani;Blood,2006

5. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukemia patients;Breccia;Hematol Oncol,2009

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data;Cancer Medicine;2024-09

2. Hematological Malignancies in Older Patients: Focus on the Potential Role of a Geriatric Assessment Management;Diagnostics;2024-06-29

3. Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia;Journal of Clinical Medicine;2024-01-03

4. Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study;Leukemia;2023-11-25

5. A Pragmatic Approach to Managing Long-Term Adverse Effects in Chronic Myeloid Leukemia Treatment;Current Hematologic Malignancy Reports;2023-05-16